United States - English - NLM (National Library of Medicine)

cardinal health - procainamide hydrochloride (unii: si4064o0lx) (procainamide - unii:l39wtc366d) - procainamide hydrochloride 100 mg in 1 ml

United States - English - NLM (National Library of Medicine)

medical purchasing solutions, llc - procainamide hydrochloride (unii: si4064o0lx) (procainamide - unii:l39wtc366d) - procainamide hydrochloride injection is indicated for the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that, in the judgement of the physician, are life-threatening. because of the proarrhythmic effects of procainamide, its use with lesser arrhythmias is generally not recommended. treatment of patients with asymptomatic ventricular premature contractions should be avoided. initiation of procainamide treatment, as with other antiarrhythmic agents used to treat life-threatening arrhythmias, should be carried out in the hospital. antiarrhythmic drugs have not been shown to enhance survival in patients with ventricular arrhythmias. because procainamide has the potential to produce serious hematological disorders (0.5 percent) particularly leukopenia or agranulocytosis (sometimes fatal), its use should be reserved for patients in whom, in the opinion of the physician, the benefits of treatment clearly outweigh the risks. (see warnings and box

United States - English - NLM (National Library of Medicine)

hf acquisition co llc, dba healthfirst - procainamide hydrochloride (unii: si4064o0lx) (procainamide - unii:l39wtc366d) - procainamide hydrochloride injection is indicated for the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that, in the judgement of the physician, are life-threatening. because of the proarrhythmic effects of procainamide, its use with lesser arrhythmias is generally not recommended. treatment of patients with asymptomatic ventricular premature contractions should be avoided. initiation of procainamide treatment, as with other antiarrhythmic agents used to treat life-threatening arrhythmias, should be carried out in the hospital. antiarrhythmic drugs have not been shown to enhance survival in patients with ventricular arrhythmias. because procainamide has the potential to produce serious hematological disorders (0.5 percent) particularly leukopenia or agranulocytosis (sometimes fatal), its use should be reserved for patients in whom, in the opinion of the physician, the benefits of treatment clearly outweigh the risks. (see warnings and boxed warning.) complete heart block: procainamide should not be administered to patients with complete heart block because of its effects in suppressing nodal or ventricular pacemakers and the hazard of asystole. it may be difficult to recognize complete heart block in patients with ventricular tachycardia, but if significant slowing of ventricular rate occurs during pa treatment without evidence of a-v conduction appearing, pa should be stopped. in cases of second degree a-v block or various types of hemiblock, pa should be avoided or discontinued because of the possibility of increased severity of block, unless the ventricular rate is controlled by an electrical pacemaker. idiosyncratic hypersensitivity: in patients sensitive to procaine or other ester-type local anesthetics, cross sensitivity to pa is unlikely. however, it should be borne in mind, and pa should not be used if it produces acute allergic dermatitis, asthma, or anaphylactic symptoms. lupus erythematosus: an established diagnosis of systemic lupus erythematosus is a contraindication to pa therapy, since aggravation of symptoms is highly likely. torsades de pointes: in the unusual ventricular arrhythmia called "les torsades de pointes" (twistings of the points), characterized by alternation of one or more ventricular premature beats in the directions of the qrs complexes on ecg in persons with prolonged q-t and often enhanced u waves, group 1a antiarrhythmic drugs are contraindicated. administration of pa in such cases may aggravate this special type of ventricular extrasystole or tachycardia instead of suppressing it.

United States - English - NLM (National Library of Medicine)

medical purchasing solutions, llc - procainamide hydrochloride (unii: si4064o0lx) (procainamide - unii:l39wtc366d) - procainamide hydrochloride injection is indicated for the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that, in the judgement of the physician, are life-threatening. because of the proarrhythmic effects of procainamide, its use with lesser arrhythmias is generally not recommended. treatment of patients with asymptomatic ventricular premature contractions should be avoided. initiation of procainamide treatment, as with other antiarrhythmic agents used to treat life-threatening arrhythmias, should be carried out in the hospital. antiarrhythmic drugs have not been shown to enhance survival in patients with ventricular arrhythmias. because procainamide has the potential to produce serious hematological disorders (0.5 percent) particularly leukopenia or agranulocytosis (sometimes fatal), its use should be reserved for patients in whom, in the opinion of the physician, the benefits of treatment clearly outweigh the risks. (see warnings and box

United States - English - NLM (National Library of Medicine)

hf acquisition co llc, dba healthfirst - procainamide hydrochloride (unii: si4064o0lx) (procainamide - unii:l39wtc366d) - procainamide hydrochloride injection is indicated for the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that, in the judgement of the physician, are life-threatening. because of the proarrhythmic effects of procainamide, its use with lesser arrhythmias is generally not recommended. treatment of patients with asymptomatic ventricular premature contractions should be avoided. initiation of procainamide treatment, as with other antiarrhythmic agents used to treat life-threatening arrhythmias, should be carried out in the hospital. antiarrhythmic drugs have not been shown to enhance survival in patients with ventricular arrhythmias. because procainamide has the potential to produce serious hematological disorders (0.5 percent) particularly leukopenia or agranulocytosis (sometimes fatal), its use should be reserved for patients in whom, in the opinion of the physician, the benefits of treatment clearly outweigh the risks. (see warnings and boxed warning.) complet

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

bausch + lomb ireland - oxybuprocaine hydrochloride 4 mg/ml - eq. oxybuprocaine 3,58 mg/ml - eye drops, solution - 4 mg/ml - oxybuprocaine hydrochloride 4 mg/ml - oxybuprocaine

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

laboratoires théa - oxybuprocaine hydrochloride 1,6 mg/0,4 ml - eye drops, solution - 0,4 % - oxybuprocaine hydrochloride 4 mg/ml - oxybuprocaine

United States - English - NLM (National Library of Medicine)

general injectables and vaccines, inc - procainamide hydrochloride (unii: si4064o0lx) (procainamide - unii:l39wtc366d) - procainamide hydrochloride injection is indicated for the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that, in the judgement of the physician, are life-threatening. because of the proarrhythmic effects of procainamide, its use with lesser arrhythmias is generally not recommended. treatment of patients with asymptomatic ventricular premature contractions should be avoided. initiation of procainamide treatment, as with other antiarrhythmic agents used to treat life-threatening arrhythmias, should be carried out in the hospital. antiarrhythmic drugs have not been shown to enhance survival in patients with ventricular arrhythmias. because procainamide has the potential to produce serious hematological disorders (0.5 percent) particularly leukopenia or agranulocytosis (sometimes fatal), its use should be reserved for patients in whom, in the opinion of the physician, the benefits of treatment clearly outweigh the risks. (see warnings and boxed warning.) complete hear

United States - English - NLM (National Library of Medicine)

henry schein, inc. - procainamide hydrochloride (unii: si4064o0lx) (procainamide - unii:l39wtc366d) - procainamide hydrochloride injection is indicated for the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that, in the judgement of the physician, are life-threatening. because of the proarrhythmic effects of procainamide, its use with lesser arrhythmias is generally not recommended. treatment of patients with asymptomatic ventricular premature contractions should be avoided. initiation of procainamide treatment, as with other antiarrhythmic agents used to treat life-threatening arrhythmias, should be carried out in the hospital. antiarrhythmic drugs have not been shown to enhance survival in patients with ventricular arrhythmias. because procainamide has the potential to produce serious hematological disorders (0.5 percent) particularly leukopenia or agranulocytosis (sometimes fatal), its use should be reserved for patients in whom, in the opinion of the physician, the benefits of treatment clearly outweigh the risks. (see warnings and boxed warning.) complete hear

Ireland - English - HPRA (Health Products Regulatory Authority)

bausch + lomb ireland limited - oxybuprocaine hydrochloride - eye drops, solution - local anesthetics; oxybuprocaine